Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | YAP1 | P46937 | 3/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235873 | 0.96 | GPR119 (0.54) | GPR119MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL22638159 | 0.90 | KIT (0.65) | GPR119MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL12916422 | 0.89 | SMN1; SMN2 (0.65) | GPR119MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6928232 | 0.88 | GPR119 (0.56) | GPR119MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL13913878 | 0.88 | SMN1; SMN2 (0.53) | GPR119MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL27390803 | 0.87 | CYP3A4 (0.55) | GPR119SMN1; SMN2ALDH1A1YAP1CYP2C19 | |
| SCHEMBL12041673 | 0.86 | GPR119 (0.57) | GPR119MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4927184 | 0.86 | GPR119 (0.54) | GPR119SMN1; SMN2YAP1KITFLT3 | |
| SCHEMBL1218834 | 0.85 | SMN1; SMN2 (0.64) | GPR119MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6263583 | 0.85 | GPR119 (0.61) | GPR119YAP1KITFLT3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366834-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| EP-1968961-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTC4S, LTB4R | GPR119 2123/4885MAPT 4389/4885KDM4E 3007/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | GPR119 1130/4885MAPT 2817/4885KDM4E 1301/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | GPR119 289/4885MAPT 3825/4885KDM4E 821/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | GPR119 1130/4885MAPT 2817/4885KDM4E 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.